{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-282783","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.056270+00:00","generated_at":"2026-06-21T22:55:20.633561+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Graybug Q3 net loss $9.8M; terminates GB-102/401 programs, cuts 20 of 28 staff","bullets":["Net loss $9.8M in Q3 2022 vs $8.0M in Q3 2021; nine-month loss $28.2M vs $27.1M.","In August 2022, terminated 20 of 28 employees and wound down GB-102 (Phase 2b) and GB-401 programs; restructuring charge $2.4M.","R&D expense fell to $3.2M from $4.0M due to program halt; G&A rose to $4.3M from $4.0M on stock-based compensation.","Cash, equivalents, and short-term investments $43.6M; cash runway beyond 2023 subject to ongoing strategic review."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-282783","json":"https://secwatch.observer/filing/0001193125-22-282783.json","markdown":"https://secwatch.observer/filing/0001193125-22-282783.md","text":"https://secwatch.observer/filing/0001193125-22-282783.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312522282783/0001193125-22-282783-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312522282783/d407208d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:55:20.633561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"311f0cd1eceba1f4e2481e7ed1b4e346bad3e541","claim":"CalciMedica, Inc. reported the nine months ended September 30, 2022 results: net income $28.2 million.","evidence_excerpt":"Net loss for the nine months ended September 30, 2022 was $28.2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312522282783/0001193125-22-282783-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2022"},{"label":"Net income","value":"$28.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"aa7b6f0f2a4194d906fbd11f63a6264d20779881","claim":"CalciMedica, Inc. reported the quarter ended September 30, 2022 results: net income $9.8 million.","evidence_excerpt":"Net loss for the quarter ended September 30, 2022 was $9.8 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312522282783/0001193125-22-282783-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"$9.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}